-
Gilead, Merck Team Up To Develop Long-Acting HIV Infection Treatments
Monday, March 15, 2021 - 11:41am | 364Read More...Gilead Sciences Inc (NASDAQ: GILD) and Merck & Co (NYSE: MRK) have entered into an agreement to co-develop and co-commercialize HIV therapies that combine Gilead's 'Lenacapavir' and Merck's 'Islatravir' into a two-drug regimen. The...
-
Pfizer, GSK-Backed ViiV First To Get FDA Approval For HIV Shots: What You Need To Know
Friday, January 22, 2021 - 1:19am | 536Read More...In a first, a monthly injectable HIV drug made by a GlaxoSmithKline plc (NYSE: GSK)- and Pfizer Inc (NYSE: PFE)-owned company has received the approval of the United States Food and Drug Administration. What Happened: The injectable — Cabenuva — is designed to replace the current...
-
Helping Patients More With Less Drugs: An Interview With CytoDyn's CEO
Wednesday, April 2, 2014 - 3:19pm | 549Read More...In a bull market, investors pile into large cap stocks to ride the wave. With the Standard & Poor's 500 Index up more than 22 percent for the last year of market action, that has certainly been the case. For the savvy investors, that offers promising opportunities in many small caps that...
